Skip to content
Canine PeptideResearch peptides

MGF dosage for a small / toy breed

under 22 lb (10 kg)

The short answer

For a dog weighing under 22 lb (10 kg), the dose of MGF reported in the literature is 20-50 mcg per day, given daily or every other day, over 4-6 weeks. It is studied in this weight class primarily for localised muscle repair, post-injury recovery. These figures are reported as published and are not recommendations — the dose for an individual dog must be set by a veterinarian who has examined the animal.

Worked examples at specific weights

Calculated from the reported range of 2–5 mcg per kg of body weight.

Body weightCalculated dose rangeFrequency
2 kg (4 lb)4–10 mcgDaily or every other day
5 kg (11 lb)10–25 mcgDaily or every other day
8 kg (18 lb)16–40 mcgDaily or every other day

For an exact figure at your dog's weight, use the dose calculator.

Typical breeds in this weight class

Chihuahua, Yorkshire Terrier, Dachshund, Pomeranian, Shih Tzu and similarly sized dogs generally fall within under 22 lb (10 kg). Weigh your dog rather than estimating — dosing is calculated per kilogram and an estimate that is out by a few kilos changes the figure materially, particularly at the smaller end.

Before dosing at all

Contraindicated with active cancer

As an IGF-1 family growth factor, MGF promotes cell proliferation. It should not be used in a dog with known or suspected malignancy.

Common questions

How much MGF for a small / toy breed?+

For a dog in the under 22 lb (10 kg) range, the reported dose is 20-50 mcg per day, given daily or every other day, typically for 4-6 weeks. At a representative weight of 5 kg (about 11 lb), that works out to roughly 10–25 mcg per dose. These figures are reported from the source literature and are not recommendations.

How often should a small / toy breed be given MGF?+

Daily or every other day is the reported frequency, over a course of 4-6 weeks. See the cycling guide for how breaks are structured.

Is MGF safe for a small / toy breed?+

MGF is among the least-studied compounds on this site in any species, and there is no canine clinical data at all — the evidence is mechanistic. Its very short half-life means systemic exposure is limited, which is reassuring, but it shares the IGF-1 family contraindication: it should not be used in a dog with known or suspected cancer, and it should not be stacked with IGF-1 LR3.

References

  1. 1.Goldspink G Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology, 2005. PMID 16174871

Educational information — not veterinary medical advice

Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.